SCHEMBL4619218

SCHEMBL4619218

Clc1ccccc1OCI

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 6/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
MAPT P10636 3/20 0.47
PKM P14618 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
TSHR P16473 1/20 0.46
RAB9A P51151 4/20 0.45
LMNA P02545 1/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 3/20 0.44
HTT P42858 2/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C19 P33261 2/20 0.44
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44
KCNH2 Q12809 1/20 0.44
TP53 P04637 1/20 0.44
DRD2 P14416 1/20 0.44
DRD4 P21917 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2092541 0.81 MEN1 (0.52) L3MBTL1MEN1KMT2AMAPTPKM
SCHEMBL9808263 0.80 L3MBTL1 (0.68) L3MBTL1MEN1KMT2AMAPTPKM
SCHEMBL668412 0.80 L3MBTL1 (0.52) L3MBTL1MEN1KMT2AMAPTPKM
SCHEMBL15153657 0.79 MRGPRX4 (0.48) L3MBTL1MEN1KMT2AMAPTPKM
SCHEMBL3944452 0.78 L3MBTL1 (0.50) L3MBTL1MEN1KMT2AMAPTPKM
SCHEMBL2094935 0.77 MEN1 (0.58) L3MBTL1MEN1KMT2AMAPTPKM
SCHEMBL11748056 0.76 L3MBTL1 (0.53) L3MBTL1MEN1KMT2AMAPTPKM
SCHEMBL2092546 0.76 MEN1 (0.52) L3MBTL1MEN1KMT2AMAPTPKM
SCHEMBL31122982 0.76 L3MBTL1 (0.62) L3MBTL1MEN1KMT2AMAPTPKM
SCHEMBL4486850 0.76 L3MBTL1 (0.48) L3MBTL1MEN1KMT2AMAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888519-A2 STYRYLSULFONAMIDES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2008-02-20 EP disclosed
WO-2007054139-A2 STYRYLSULFONAMIDES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2007-05-18 WO disclosed
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270874-A1 Styrylsulfonamides STS, SULT1E1, BRCA1 L3MBTL1 2082/4885MEN1 1331/4885KMT2A 2935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.